Searched for
REVLIMID SALES
Dr Reddy's bets on generic semaglutide, biosimilarsDr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...
- Dr Reddy's Q3 preview: PAT may fall 22% YoY as US pressure to weigh on earningsDr Reddy's Laboratories anticipates a subdued performance for the December quarter. Pressure from its United States business is expected to...
- Can DRL’s new product launches offset the slowdown in Revlimid sales?Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US...
- Drug companies set for improved revenue growth in June quarter amid US market challengesIndian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. H...
- Dr. Reddy's Q3 Preview: PAT may rise 10% YoY; US sales to be stableDr. Reddy's net profit for the third quarter is expected to grow 10% YoY, with revenues likely increasing 13% YoY, based on an average of f...
- HSBC bullish on Indian pharma stocks for 2025The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.
- Dr Reddy's Labs Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fallAnalysts project U.S. revenue at $419 million, supported by a strong contribution from gRevlimid. The India business is expected to grow 19...
- Dr Reddy's Q1 Preview: PAT may fall 4% YoY on pricing pressure, subdued US salesIn the preceding March quarter, Dr Reddy's reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue f...
- Alembic Pharma Q4 Results: Posts higher profit on strong N.America salesAlembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by stro...
- Dr Reddy’s Q3 Results Preview: Profit may drop on lower Revlimid sales, higher costsThe drugmaker is expected to report a 1.1% YoY drop in consolidated net profit to Rs 1,247 crore, according to the average of estimates giv...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Hot Stocks: Brokerages on Bajaj Auto, Dr Reddy’s Laboratories, Tata Motors and Cipla post Q3 resultsEBITDA margin improved by 176 bps YoY to 24.2% despite soft Revlimid sales, mainly driven by an improvement in the mix. The net profit grew...
- Dr Reddy's Laboratories sees generic Revlimid, other launches to keep US business firingThe Hyderabad-based drug maker on Friday reported its highest ever revenues, largely driven by generic Revlimid launch during the second qu...
- Natco Pharma announces launch of first generic of top selling cancer drug RevlimidRevlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. The generic version of Revlimid will be available i...
- Buy Natco Pharma, target price Rs 954: ICICI SecuritiesNatco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 16894.09 Crore) operating in Pharmaceutic...
- DRL seeks USFDA help to make cancer drug cloneUS-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.
Load More
